Oncogen
55Patents
0Active
55Granted
36Portfolio score
Filing activity: Mar 23, 1984 → Sep 22, 1995
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5204244A | Production of chimeric antibodies by homologous recombination | Chemistry; Metallurgy | 250 | Expired |
| US5202238A | Production of chimeric antibodies by homologous recombination | Chemistry; Metallurgy | 201 | Expired |
| US5314995A | Therapeutic interleukin-2-antibody based fusion proteins | Emerging Cross-Sectional Technologies | 162 | Expired |
| US5171665A | Monoclonal antibody to novel antigen associated with human tumors | Emerging Cross-Sectional Technologies | 122 | Expired |
| US5134075A | Monoclonal antibody to novel antigen associated with human tumors | Emerging Cross-Sectional Technologies | 110 | Expired |
| US5645835A | Therapeutic antibody based fusion proteins | Emerging Cross-Sectional Technologies | 91 | Expired |
| US4918164A | Tumor immunotherapy using anti-idiotypic antibodies | Emerging Cross-Sectional Technologies | 75 | Expired |
| US5482856A | Production of chimeric antibodies by homologous recombination | Chemistry; Metallurgy | 67 | Expired |
| US5262177A | Recombinant viruses encoding the human melanoma-associated antigen | Physics | 61 | Expired |
| US5120535A | Oncostatin M and novel compositions having anti-neoplastic activity | Chemistry; Metallurgy | 48 | Expired |
| US5091178A | Tumor therapy with biologically active anti-tumor antibodies | Emerging Cross-Sectional Technologies | 45 | Expired |
| US5081029A | Methods of adoptive immunotherapy for treatment of aids | Chemistry; Metallurgy | 43 | Expired |
| US5242824A | Monoclonal antibody to human carcinomas | Chemistry; Metallurgy | 42 | Expired |
| US5597578A | TGF-.beta. protein compositions for inhibition of cell proliferation | Human Necessities | 41 | Expired |
| US5221620A | Cloning and expression of transforming growth factor .beta.2 | Chemistry; Metallurgy | 41 | Expired |
| US4997913A | pH-sensitive immunoconjugates and methods for their use in tumor therapy | Emerging Cross-Sectional Technologies | 39 | Expired |
| US4906562A | Monocolonal antibodies and antigen for human non-small cell lung carcinomas | Emerging Cross-Sectional Technologies | 33 | Expired |
| US5340925A | Normal human growth regulatory receptor for TGF-.beta. | Chemistry; Metallurgy | 32 | Expired |
| US5091177A | Monoclonal antibodies for treatment of human non-small cell lung carcinomas | Emerging Cross-Sectional Technologies | 30 | Expired |
| US5491088A | Monoclonal antibody BR 96 and chimeric monoclonal antibodies having the variable region of MAB BR96, which bind to a variant of ley antigen on human carcimona cells | Chemistry; Metallurgy | 29 | Expired |
| US5141742A | Vaccines against melanoma | Human Necessities | 28 | Expired |
| US4645828A | Platelet related growth regulator | Emerging Cross-Sectional Technologies | 25 | Expired |
| US4737579A | Monoclonal antibodies for human non-small cell lung carinomas | Emerging Cross-Sectional Technologies | 25 | Expired |
| US4935495A | Monoclonal antibodies to the L6 glycolipid antigenic determinant found on human non-small cell lung carcinomas | Emerging Cross-Sectional Technologies | 23 | Expired |
| US5786456A | Bp 50-specific antibodies and fragments thereof | Chemistry; Metallurgy | 23 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.